Form 4: Cingulate Inc. Grants Stock Options to EVP and CSO Raul R. Silva

Cingulate Inc.'s Executive Vice President and Chief Scientific Officer, Raul R. Silva, was granted 51,500 stock options with an exercise price of $4.42, vesting over a four-year period.

Summary

• Raul R. Silva, Executive Vice President and Chief Scientific Officer of Cingulate Inc. (CING), was granted 51,500 stock options.
• The stock options have an exercise price of $4.42 per share.
• The grant date for these options is July 7, 2025.
• The options will expire on July 7, 2035.
• Vesting of the options will occur with 25% on the one-year anniversary of the grant date (July 7, 2026), and the remaining shares will vest in substantially equal monthly installments over the subsequent 36-month period.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management incentives with shareholder interests, though it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 51,500 stock options to a key executive like Raul R. Silva aligns management incentives with long-term shareholder interests.
• The long expiration date of July 7, 2035, provides a significant window for the executive to benefit from potential future stock price appreciation.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This Form 4 filing reflects a standard executive compensation practice within the biotechnology and pharmaceutical industries, where stock options are commonly used to incentivize key personnel and align their interests with long-term company performance and value creation.

Comparison to Industry Standards

• The grant of stock options to an Executive Vice President and Chief Scientific Officer is a common practice in the biotech and pharmaceutical sectors, comparable to compensation structures seen at companies like Moderna, BioNTech, or Pfizer, where executive incentives are often tied to equity performance.
• The vesting schedule, which includes an initial cliff vesting followed by monthly installments over three years, is a typical industry standard designed to encourage long-term retention and performance from key executives.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with the company's long-term stock performance.
• Employees: No direct impact mentioned, but this type of executive compensation can signal stability in leadership.

Next Steps

• Continued vesting of the granted stock options according to the specified schedule, with the first 25% vesting on July 7, 2026.

Key Dates

Keywords

Cingulate Inc., CING, Stock Options, Executive Compensation, Insider Transaction, Form 4, Raul R. Silva, EVP, CSO